Characterization of the Langendorff Perfused Isolated Mouse Heart Model of Global Ischemia-Reperfusion Injury: Impact of Ischemia and Reperfusion Length on Infarct Size and LDH Release

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 21, Issue 3, 2016, Pages 286-295

  Rossello, Xavier ^a   Hall, Andrew R ^a   Bell, Robert M ^a   Yellon, Derek M ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

ischemia preconditioning; ischemia reperfusion; myocardial infarction

Indexed keywords

LACTATE DEHYDROGENASE; BIOLOGICAL MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME RELEASE; FACTORIAL DESIGN; HEART INFARCTION SIZE; HEART PERFUSION; ISOLATED HEART; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; ANIMAL; AREA UNDER THE CURVE; C57BL MOUSE; CARDIAC MUSCLE; COMPARATIVE STUDY; DISEASE MODEL; ENZYMOLOGY; HEART INFARCTION; HEART MUSCLE REPERFUSION; METABOLISM; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY; STAINING; TIME FACTOR;

ANIMALS; AREA UNDER CURVE; BIOMARKERS; DISEASE MODELS, ANIMAL; ISOLATED HEART PREPARATION; L-LACTATE DEHYDROGENASE; MALE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; STAINING AND LABELING; TIME FACTORS;

EID: 84963657707     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248415604462     Document Type: Article

References (31)

1. Lecour S, Bøtker HE, Condorelli G, et al. ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovasc Res. 2014; 104 (3): 399-411.
2. Sutherland FJ, Hearse DJ,. The isolated blood and perfusion fluid perfused heart. Pharmacol Res. 2000; 41 (6): 613-627.
3. Sharma V, Kearney MT, Davidson SM, Yellon DM,. Endothelial insulin resistance protects the heart against prolonged ischemia-reperfusion injury but does not prevent insulin transport across the endothelium in a mouse Langendorff model. J Cardiovasc Pharmacol Ther. 2014; 19 (6): 586-591.
4. Bell RM, Smith CCT, Yellon DM,. Nitric oxide as a mediator of delayed pharmacological (A(1) receptor triggered) preconditioning; is eNOS masquerading as iNOS? Cardiovasc Res. 2002; 53 (2): 405-413.
5. Skyschally A, van Caster P, Iliodromitis EK, Schulz R, Kremastinos DT, Heusch G,. Ischemic postconditioning: experimental models and protocol algorithms. Basic Res Cardiol. 2009; 104 (5): 469-483.
6. Sumeray MS, Yellon DM,. Characterisation and validation of a murine model of global ischaemia-reperfusion injury. Mol Cell Biochem. 1998; 186 (1-2): 61-68.
7. Sumeray MS, Yellon DM,. Ischaemic preconditioning reduces infarct size following global ischaemia in the murine myocardium. Basic Res Cardiol. 1998; 93 (5): 384-390.
8. Wang QD, Swärdh A, Sjöquist PO,. Relationship between ischaemic time and ischaemia/reperfusion injury in isolated Langendorff-perfused mouse hearts. Acta Physiol Scand. 2001; 171 (2): 123-128.
9. Headrick JP, Peart J, Hack B, Flood A, Matherne GP,. Functional properties and responses to ischaemia-reperfusion in Langendorff perfused mouse heart. Exp Physiol. 2001; 86 (6): 703-716.
10. Bell RM,. The Role of Nitric Oxide in Myocardial Ischaemia/Reperfusion Injury [DPhil Thesis]. 2001. United Kingdom: University College London.
11. Siddall HK,. The role of PTEN in cardioprotection against ischaemia-reperfusion injury [DPhil Thesis]. 2009. United Kingdom: University College London.
12. Bell RM, Mocanu MM, Yellon DM,. Retrograde heart perfusion: the Langendorff technique of isolated heart perfusion. J Mol Cell Cardiol. 2011; 50 (6): 940-950.
13. Klein HH, Puschmann S, Schaper J, Schaper W,. Vircho Archiv A The Mechanism of the Tetrazolium Reaction in Identifying Experimental Myocardial Infarction. Virchows Arch [Pathol Anat]. 1981; 393 (3): 287-297.
14. Khaliulin I, Parker JE, Halestrap AP,. Consecutive pharmacological activation of PKA and PKC mimics the potent cardioprotection of temperature preconditioning. Cardiovasc Res. 2010; 88 (2): 324-333.
15. Povlsen JA, Løfgren B, Dalgas C, Jespersen NR, Johnsen J, Bøtker HE,. Frequent biomarker analysis in the isolated perfused heart reveals two distinct phases of reperfusion injury. Int J Cardiol. 2014; 171 (1): 9-14.
16. Fernández-Jiménez R, Silva J, Martínez-Martínez S, et al. Impact of left ventricular hypertrophy on troponin release during acute myocardial infarction: new insights from a comprehensive translational study. J Am Heart Assoc. 2015; 4 (1): e001218.
17. Cox DR,. Planning of Experiments. 2nd ed. New York, NY: John Wiley & Sons; 1992.
18. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG,. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010; 8 (6): e1000412.
19. Redel A, Jazbutyte V, Smul TM, et al. Impact of ischemia and reperfusion times on myocardial infarct size in mice in vivo. Exp Biol Med (Maywood). 2008; 233 (1): 84-93.
20. Ferrera R, Benhabbouche S, Bopassa JC, Li B, Ovize M,. One hour reperfusion is enough to assess function and infarct size with TTC staining in Langendorff rat model. Cardiovasc Drugs Ther. 2009; 23 (4): 327-331.
21. Ibáñez B, Heusch G, Ovize M, Van de Werf F,. Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 2015; 65 (14): 1454-1471.
22. McAlindon E, Bucciarelli-Ducci C, Suleiman MS, Baumbach A,. Infarct size reduction in acute myocardial infarction. Heart. 2015; 101 (2): 155-160.
23. Heusch G,. Cardioprotection: chances and challenges of its translation. Lancet. 2013; 381 (9861): 166-175.
24. Yellon DM, Hausenloy DJ,. Myocardial reperfusion injury. N Engl J Med. 2007; 357 (11): 1121-1135.
25. Schwarz ER, Somoano Y, Hale SL, Kloner RA,. What is the required reperfusion period for assessment of myocardial infarct size using triphenyltetrazolium chloride staining in the rat? J Thromb Thrombolysis. 2000; 10 (2): 181-187.
26. Birnbaum Y, Hale SL, Kloner RA,. Differences in reperfusion length following 30 minutes of ischemia in the rabbit influence infarct size, as measured by triphenyltetrazolium chloride staining. J Mol Cell Cardiol. 1997; 29 (2): 657-666.
27. Ibanez B, Macaya C, Sánchez-Brunete V, et al. Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) tri. Circulation. 2013; 128 (14): 1495-503. doi:10.1161/CIRCULATIONAHA.113.003653.
28. Murry CE, Jennings RB, Reimer KA,. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74 (5): 1124-1136.
29. Kloner RA,. No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharmacol Ther. 16 (3-4): 244-250.
30. Stensløkken K-O, Rutkovskiy A, Kaljusto M-L, Hafstad AD, Larsen TS, Vaage J,. Inadvertent phosphorylation of survival kinases in isolated perfused hearts: a word of caution. Basic Res Cardiol. 2009; 104 (4): 412-423.
31. Anderson PG, Bishop SP, Digerness SB,. Transmural progression of morphologic changes during ischemic contracture and reperfusion in the normal and hypertrophied rat heart. Am J Pathol. 1987; 129 (1): 152-167.